What is the classification of Fludarabine (Fludara) in cancer treatment?

Fludarabine, commonly known by the brand name Fludara, is classified as a cytotoxic agent in cancer treatment. This classification is based on its mechanism of action, which involves interfering with the DNA synthesis of rapidly dividing cancer cells. Fludarabine is an analog of the nucleoside adenosine, and it is incorporated into the DNA during replication, leading to the disruption of normal cellular functions and ultimately causing cell death.

Cytotoxic agents are often used in chemotherapy regimens to target cancer cells due to their high proliferation rates. Fludarabine is particularly effective in treating certain types of hematological malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma.

In contrast, targeted therapy concentrates on specific cancer-related molecules, hormonal therapy focuses on hormone-responsive cancers, and immunotherapy aims to activate or enhance the immune response against cancer cells. Fludarabine's direct action on DNA synthesis and its role in traditional chemotherapy categorize it distinctly as a cytotoxic agent.